Biotest will more than double the production capacity of the Biotest Group with the "Biotest Next Level" investment programme. This programme includes the construction of a basic plasma fractionation facility with 1.4 million litre capacity, and bulk production plants for Albumin, new Fibrinogen and Trimodulin (IgM Concentrate) product lines, and next-generation polyvalent immunoglobulins.
The new production building, which is supplied by its own combined heat and power plant energy centre, was built according to the latest regulations of the German energy-saving regulations (EnEV 2015) and the German renewable energy act.